Brodalumab

證據等級: L5

預測適應症: 10 個

Brodalumab: From an Unspecified Original Indication to Strongyloidiasis (Flagged as a Reversed-Direction Signal)

One-Sentence Summary

Brodalumab's original indication is not recorded in this evidence pack, though it is known to act as an IL-17RA antagonist. The TxGNN model's top prediction — Strongyloidiasis — is not supported by any clinical trials or literature, and the model's own mechanistic rationale indicates the association runs in the opposite direction: IL-17 blockade is a known risk factor for strongyloidiasis, not a treatment for it. This is best read as a safety signal miscaptured as a repurposing opportunity, not a viable candidate.

Quick Overview

Item	Content
Original Indication	Not provided in this evidence pack (`original_indications` empty)
Predicted New Indication	Strongyloidiasis ⚠️ (mechanistically reversed — see below)
TxGNN Prediction Score	99.84%
Evidence Level	L5 (no clinical trials, no literature)
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism-of-action data (DrugBank original_moa) is not available in this evidence pack. However, the model's own rationale annotations identify brodalumab as an IL-17RA (interleukin-17 receptor A) antagonist, which blocks IL-17-mediated signaling. IL-17RA-targeting biologics as a class are used to suppress IL-17-driven inflammatory responses.

The original indication field is empty in this pack, so no direct comparison to the predicted indication can be made from the structured data. What can be assessed is the mechanistic plausibility of the top-ranked prediction on its own terms — and here the evidence pack flags a critical problem.

This prediction is not reasonable, and the evidence pack itself says so. IL-17 is a key host-defense cytokine against intestinal nematodes, including Strongyloides stercoralis. Clinically, IL-17 pathway inhibitors (brodalumab, secukinumab, and related agents) are known to increase the risk of strongyloidiasis reactivation/hyperinfection — package inserts for this drug class typically require screening and treatment of latent strongyloidiasis before initiating therapy. TxGNN's topological similarity scoring appears to have picked up a real biological relationship (IL-17RA ↔ strongyloidiasis) but assigned it the wrong causal direction — a known failure mode where "risk association" and "therapeutic indication" edges are conflated in the knowledge graph. This should be treated as a contraindication signal, not a repurposing lead.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Brodalumab has 0 authorizations on record and is not marketed in Norway (未上市) per this evidence pack. No license entries are available to tabulate.

Safety Considerations

Mechanistic Safety Signal (from prediction rationale, not formal labeling): The evidence pack's own analysis notes that IL-17 pathway blockade — the mechanism of brodalumab — is associated with an increased risk of Strongyloides infection/hyperinfection syndrome. This mirrors known class-level guidance for IL-17 inhibitors requiring strongyloidiasis screening prior to treatment initiation.
Formal package insert warnings, contraindications, and drug-drug interaction data are not available in this evidence pack (flagged as a Blocking data gap, DG001). Please refer to the official package insert for complete safety information once available.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (strongyloidiasis) is directionally inverted — it describes a known risk of the drug's mechanism, not a therapeutic opportunity — and carries zero supporting clinical trials or literature (L5). No other candidate in the top 10 (ranks 2–10, all ophthalmic/inflammatory conditions) reaches beyond L4/L5, and several (e.g., isolated optic neuritis) carry their own directional uncertainty, since IL-17 inhibitors have been associated with case reports of CNS demyelinating disease exacerbation.

To proceed, the following is needed:

Formal DrugBank/TFDA data for original indication and MOA, to establish a true baseline for mechanistic comparison
TFDA package insert (warnings, contraindications, DDI) to close Blocking data gap DG001
Any brodalumab-specific (not class-level) case reports or pharmacovigilance data on strongyloidiasis, to confirm risk directionality rather than infer it
If pursuing the optic neuritis/CRION cluster (ranks 5–8) as a longer-shot hypothesis, targeted literature search for Th17/IL-17 involvement in demyelinating optic neuropathies, alongside explicit review of CNS demyelination risk associated with IL-17 inhibitor use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.